Review of international scientific data on the polyzhinax use in the treatment and prevention of vaginitis of different etiology

Authors

  • Е. Ф. Кира N.I. Pirogov NMSC, Moscow, Russian Federation, Russian Federation https://orcid.org/0000-0002-1376-7361
  • А. М. Савічева FSBI “D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology”, Moscow, Russian Federation, Russian Federation

Keywords:

vaginal infections, bacterial vaginosis, nonspecific vaginitis, vulvovaginal candidiasis, neomycin sulfate, polymyxin B sulphate, nystatin, Polygynax

Abstract

A significant prevalence of infectious-inflammatory diseases of female genital organs is one of the most urgent problems of gynecology. The combination of various bacterial and bacterial-fungal associations of microorganisms in the vaginal biotope leads to the formation of complex indistinct clinical manifestations, which complicates diagnosis. Incorrect diagnosis and inadequate treatment increase the frequency of vaginal infection relapses and contribute to prolonged course of the disease.

Polygynax as one of the long-established drugs in Ukraine has not lost its significance despite the emergence in the national pharmaceutical market of an increasing number of drugs for local treatment and prevention of vulvovaginal infections. This medicinal product contains neomycin sulfate, polymyxin B sulphate and nystatin. The choice in its favor is based on a large array of accumulated data, which has shown its high efficiency and safety for the treatment and prevention of vulvovaginal infections in reproductive aged women.

Based on the described in the article researches, the wide spectrum of the polygynax encompasses the main pathogens of bacterial and fungal vaginitis. Polygynax showed high efficacy against C. albicans strains, and especially in C. non-albicans resistant strains (including fluconazole resistant strains). Unlike oral medications, local treatment makes it possible to avoid the development of resistance to pathological microflora. Polygynax does not suppress normal vaginal flora and does not disturb its balance. Due to its characteristics, it is a drug of choice for local therapy of vaginitis. This is especially true in cases where, for a number of reasons, treatment should be initiated immediately, before obtaining the results of a microbiological study. In addition, the benefits of this drug should also include the simplicity and ease of use, the absence of absolute contraindications, the possibility of use in patients with extragenital pathology, in adolescents and postmenopausal women, and the local route of administration can reduce the pharmacological burden on the body.

Author Biographies

Е. Ф. Кира, N.I. Pirogov NMSC, Moscow, Russian Federation

MD, professor, academician of the Russian Academy of Natural Sciences, head of the women’s diseases and reproductive health Department, Institute for the Advanced Training of Doctors

А. М. Савічева, FSBI “D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology”, Moscow, Russian Federation

MD, professor, head of microbiology laboratory

References

  1. Esim, B.E., Kars, B., Karsidag, A.Y., et al. “Diagnosis of vulvovaginitis: comparison of clinical and microbiological diagnosis.” Arch Gynecol Obstet 282.5 (2010): 515–9.
  2. Mylonas, I., Bergauer, F. “Diagnosis of vaginal discharge by wet mount microscopy: a simple and underrated method.” Obstet Gynecol Surv 66.6 (2011): 359–68.
  3. Gajer, P., Brotman, R.M., Bai, G., et al. “Temporal dynamics of the human vaginal microbiota.” Sci Trans Med 4.132 (2012):132–52.
  4. Huang, B., Fettweis, J.M., Brooks, J.P., et al. “The changing landscape of the vaginal microbiome.” Clin Lab Med 34 (2014): 747–61.
  5. Jasarevic, E., Howerton, C.L., Howard, C.D., Bale, T.L. “Alterations in the vaginal microbiome by maternal stress are associated with metabolic reprogramming of the offspring gut and brain.” Endocrinology 156 (2015): 3265–76.
  6. Oh, H.Y., Seo, S.S., Kong, J.S., et al. “Association between obesity and cervical microflora dominated by Lactobacillus iners in Korean women.” J Clin Microbiol 53 (2015): 3304–9.
  7. Brotman, R.M., He, X., Gajer, P., et al. “Association between cigarette smoking and the vaginal microbiota: a pilot study.” BMC Infect Dis 14 (2014): 471.
  8. Olina, A.A. Non-specific infectious diseases of the vagina (medical and social, etiological, clinical and diagnostic features). Thesis abstract for PhD degree. Perm (2009): 24 p.
  9. Hay, P., Donders, G., Giraldo, P., Lepargneur, J.P. “Key Opinions in Medicine. New Perspectives in the Diagnosis and Treatment of Vaginal Infections.” Obstet Gynaecol 2.1 (2017).
  10. Donders, G.G., Vereecken, A., Bosmans, E., et al. “Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis.” BJOG 109 (2002): 34-43.
  11. Kenyon, C., Colebunders, R., Crucitti, T. “The global epidemiology of bacterial vaginosis: a systematic review.” Am J Obstet Gynecol 209.6 (2013): 505–23.
  12. Donders, G.G., Ruban, K., Bellen, G. “Selecting anti-microbial treatment of aerobic vaginitis.” Curr Infect Dis Rep 17.5 (2015): 47.
  13. Liang, Q., Li, N., Song, S., et al. “High-dose nifuratel for simple and mixed aerobic vaginitis: A single-center prospective open-label cohort study.” J Obstet Gynaecol Res 42.10 (2016): 1354–60.
  14. The Centers for Disease Control and Prevention. “Vulvovaginal candidiasis. Sexually transmitted diseases treatment guidelines.” MMWR 59 (2010): 61–3.
  15. Sobel, J.D. “Vulvovaginal candidiasis.” Lancet 369 (2007): 1961.
  16. Paulitsch, A., Weger, W., Ginter-Hanselmayer, G., et al. “A 5-year (2000–2004) epidemiological survey of Candida and non-Candida yeast species causing vulvovaginal candidiasis in Graz, Austria.” Mycoses 49 (2006): 471–5.
  17. Donders, G.G., Bosmans, E., Dekeersmaecker, A., et al. “Pathogenesis of abnormal vaginal bacterial flora.” Am J Obstet Gynecol 182.4 (2000): 872–8.
  18. Sobel, J.D., Subramanian, C., Foxman, B., et al. “Mixed vaginitis-more than coinfection and with therapeutic implications.” Curr Infect Dis Rep 15.2 (2013): 104–8.
  19. Bohbot, J.-M., Sednaoui, P., Verriere, F. “Nystatin-Neomycin-Polymyxin B Combination: Efficacy and Tolerance as 1st-Line Local Treatment of Infectious Vaginitis.” Open J Obstet Gynecol 4 (2014): 445–54.
  20. Landers, D.V., Wiesenfeld, H.C., Heine, R.P., et al. “Predictive Value of the Clinical Diagnosis of Lower Genital Tract Infection in Women.” Am J Obstet Gynecol 190 (2004): 1004–8.
  21. Report of the Nosocotech laboratory (Lyon, France). “Comparative evaluation of the activity of the constituent drugs Polygynax and Terzhinan in vitro.” Medical aspects of women’s health. Special issue. Infections in obstetrics and gynecology (2012): 22–4.
  22. Boisnik, S., Branchet, M.С. “Evaluation of the anti-inflammatory effect of the drug Polygynax.” Medical aspects of women’s health 4.56 (2012): 22–8.
  23. Nolewajka-Lasak, I., Rajca, M., Kamiński, K., et al. “Antibiotic sensitivity of Enterobacteriaceae isolated from women vagina and uterine cervix.” Med Dosw Mikrobiol 55.4 (2003): 351–6.
  24. Paterson, D.L. “Resistance in gram-negative bacteria: enterobacteriaceae.” Am J Med 119.6 Suppl. 1 (2006): 20–8.
  25. Vermitsky, J.P., Self, M.J., Chadwick, S.G., et al. “Survey of vaginal flora Candida species isolates from women of different age groups by use of species-specific PCR detection.” J Clin Microbiol 46 (2008): 1501–3.
  26. Richter, S.S., Galask, R.P., Messer, S.A., et al. “Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.” J Clin Microbiol 43 (2005): 2155–62.
  27. Donders, G.G., Bellen, G., Mendling, W. “Management of recurrent vulvovaginal candidosis as a chronic illness.” Gynecol Obstet Invest 70 (2010): 306–21.
  28. Sherrard, J., Donders, G., White, D., Jensen, J.S.; European IUSTI. “European (IUSTI/WHO) guideline on the management of vaginal discharge, 2011.” J STD AIDS 22 (2011): 4211–9.
  29. Choukri, F., Benderdouche, M., Sednaoui, P. “In vitro susceptibility profile of 200 recent clinical isolates of Candida spp. to topical antifungal treatments of vulvovaginal candidiasis, the imidazoles and nystatin agents.” J Mycol Med 24 (2014): 303–7.
  30. Achkar, J.M., Fries, B.C. “Candida infections of the genitourinary tract.” Clin Microbiol Rev 23 (2010): 253–73.
  31. Neut, C., Verriere, F., Nelis, H.J., Coenye, T. “Topical Treatment of Infectious Vaginitis: Effects of Antibiotic, Antifungal and Antiseptic Drugs on the Growth of Normal Vaginal Lactobacillus Strains.” Open J Obstet Gynecol 5 (2015): 173–80.
  32. Guidelines for outpatient care in obstetrics and gynecology. Ed. by V.E. Radzinsky. 2nd ed., rew. and add. Moscow. GEOTAR-Media (2014): 944 p.
  33. Kira, E.F., Artymuk, N.V., Gaitukieva, R.A., Muslimova, S.Z. “Biocenosis and functional activity of the vaginal epithelium in the local treatment of aerobic vaginitis with polygynax and terzhinan.” Journal of Obstetrics and Female Diseases LIX.5 (2010): 127–35.
  34. Radzinsky, V.E., Ordiyants, I.M., Pobedinskaya, O.S., Zykov, E.V. “Experience of using the drug Poliginax in the treatment of vulvovaginitis caused by aerobic and mixed microflora.” Russian Bulletin of the obstetrician-gynecologist 1 (2016): 45–8.

Downloads

Published

2018-12-28

How to Cite

Кира, Е. Ф., & Савічева, А. М. (2018). Review of international scientific data on the polyzhinax use in the treatment and prevention of vaginitis of different etiology. REPRODUCTIVE ENDOCRINOLOGY, (44), 50–58. Retrieved from https://reproduct-endo.com/article/view/153337

Issue

No. 44 (2018)

Section

Drug therapy

License

Copyright (c) 2018 Е. Ф. Кира, А. М. Савічева

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.